Literature DB >> 2153457

Integration of human papillomavirus 16 DNA and genomic rearrangements in immortalized human keratinocyte lines.

N C Popescu1, J A DiPaolo.   

Abstract

Five foreskin-derived keratinocyte lines, immortalized by transfection of human papillomavirus (HPV16) DNA, were cytogenetically abnormal, exhibiting numerical deviations and altered chromosomes due to translocations, deletions, achromatic lesions, or partial duplications. Furthermore, all lines had cells with either homogeneously staining regions or double minute chromosomes, alterations associated with malignancy or drug resistance. None of these lines were tumorigenic in nude mice, showing that such alterations which are a manifestation of DNA amplification also occur in nonneoplastic cells. By in situ chromosome hybridization, viral sequences were identified on abnormal chromosomes at the junction of chromosome translocations, at achromatic lesions and within homogeneously staining regions and duplicated chromosome segments. Thus, for the first time in an experimental system, HPV16 integration into the cellular genome was associated with the induction of a subset of chromosome alterations. HPV16 integration that frequently occurred at fragile sites and near protooncogenes may be a critical alteration which confers a selective growth advantage and an indefinite proliferative potential to HPV-transfected cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153457

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Epigenetics of human papillomaviruses.

Authors:  Eric Johannsen; Paul F Lambert
Journal:  Virology       Date:  2013-08-13       Impact factor: 3.616

2.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

3.  Episomal and integrated human papillomavirus in cervical neoplasia shown by non-isotopic in situ hybridisation.

Authors:  K Cooper; C S Herrington; J E Stickland; M F Evans; J O McGee
Journal:  J Clin Pathol       Date:  1991-12       Impact factor: 3.411

Review 4.  Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.

Authors:  Niladri Ganguly
Journal:  Cell Oncol (Dordr)       Date:  2012-01-20       Impact factor: 6.730

Review 5.  HPV epigenetic mechanisms related to Oropharyngeal and Cervix cancers.

Authors:  Marina Di Domenico; Giancarlo Giovane; Soumaya Kouidhi; Rosamaria Iorio; Maurizio Romano; Francesco De Francesco; Antonia Feola; Camilla Siciliano; Luigi Califano; Antonio Giordano
Journal:  Cancer Biol Ther       Date:  2018-05-14       Impact factor: 4.742

Review 6.  Human papillomaviruses and cervical neoplasia. I. Classification, virology, pathology, and epidemiology.

Authors:  C S Herrington
Journal:  J Clin Pathol       Date:  1994-12       Impact factor: 3.411

7.  Establishment and characterization of an HPV16 E6/E7-expressing oral squamous cell carcinoma cell line with enhanced tumorigenicity.

Authors:  Dongxia Ye; Xiaojian Zhou; Hongya Pan; Qian Jiang; Laiping Zhong; Wantao Chen; Zhiyuan Zhang
Journal:  Med Oncol       Date:  2010-05-13       Impact factor: 3.064

8.  Transforming growth factors beta 1 and 2 transcriptionally regulate human papillomavirus (HPV) type 16 early gene expression in HPV-immortalized human genital epithelial cells.

Authors:  C D Woodworth; V Notario; J A DiPaolo
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

Review 9.  Molecular mechanisms of human papillomavirus-induced carcinogenesis.

Authors:  Michaël Lehoux; Claudia M D'Abramo; Jacques Archambault
Journal:  Public Health Genomics       Date:  2009-08-11       Impact factor: 2.000

10.  Coexistence of episomal and integrated HPV16 DNA in squamous cell carcinoma of the cervix.

Authors:  E Kristiansen; A Jenkins; R Holm
Journal:  J Clin Pathol       Date:  1994-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.